eribulin + erlotinib

Eribulin + erlotinib is a combination therapy that has been studied in clinical trials for various cancer types. Eribulin (brand name Halaven) is a microtubule dynamics inhibitor, while erlotinib (brand name Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. ## Mechanism of Action This combination leverages complementary mechanisms of action. Eribulin works by inhibiting microtubule dynamics, which disrupts the mitotic spindle and leads to cell cycle arrest and apoptosis in cancer cells[3][5]. Erlotinib targets the EGFR pathway, inhibiting tyrosine kinase activity and blocking cell signaling pathways involved in cell proliferation and survival[7]. ## Clinical Evidence Preclinical studies have demonstrated that eribulin shows combination activity with multiple agents from different mechanistic classes, including erlotinib, in several human cancer models such as breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and melanoma[3][5]. This suggests potential synergistic effects when these drugs are used together. Research has shown that eribulin can be favorably combined with a broad set of anticancer agents from diverse mechanistic classes, consistent with its effects on tumor biology beyond purely antimitotic activities[5]. The combination of eribulin with targeted agents like erlotinib has demonstrated promising results in preclinical xenograft models[3][4]. ## Development Status While specific phase 3 trials for the eribulin + erlotinib combination were not detailed in the search results, there is evidence of a Phase 2 multicenter randomized study evaluating different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with lung cancer[2]. ## Safety Profile The safety profile of this combination would likely include the known side effects of both medications. For eribulin, common adverse events include neutropenia (occurring in 57% of patients), fatigue, and peripheral sensory neuropathy[6][8]. For erlotinib, common side effects include skin reactions and diarrhea[8]. The combination therapy would require careful monitoring for potential additive toxicities, particularly QTc prolongation, which can be increased when eribulin is combined with erlotinib[7].

Brand names

HalavenTarceva

Other names

eribulinhalichondrin B analog